(2020). AR-V7 as a biomarker for resistance to treatment with abiraterone/enzalutamide in three Latin American countries: A hypothetical cost-saving analysis.
Chicago Style (17th ed.) CitationAR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/enzalutamide in Three Latin American Countries: A Hypothetical Cost-saving Analysis. 2020.
MLA (8th ed.) CitationAR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/enzalutamide in Three Latin American Countries: A Hypothetical Cost-saving Analysis. 2020.
Warning: These citations may not always be 100% accurate.